Search research articles
Contact Us
Filters
Showing results (121-130 of 168) with videos related to
Page
of 17
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2011
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
J-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2007
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
J Bellmunt, L Paz-Ares, M Cuello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2015
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
P G Nuciforo, C Aura, E Holmes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
J-C Soria, J Cortes, C Massard, et al.
Cancer Investigation
|
March 26, 1998
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel
C Hudis, L Riccio, A Seidman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
J Baselga, A Manikhas, J Cortés, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy
C Hudis, A Seidman, J Baselga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2014
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
J Baselga, A Manikhas, J Cortés, et al.
Breast Cancer Research and Treatment
|
May 19, 2015
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
Miguel J Gil-Gil, M Bellet, S Morales, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Page
of 17
Search research articles
Search
Showing results (121-130 of 168) with videos related to
Sort By:
Page
of 17
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2011
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
J-C Soria, J Cortes, C Massard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 19, 2007
Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
J Bellmunt, L Paz-Ares, M Cuello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2015
Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
P G Nuciforo, C Aura, E Holmes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors
J-C Soria, J Cortes, C Massard, et al.
Cancer Investigation
|
March 26, 1998
Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel
C Hudis, L Riccio, A Seidman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2019
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
J Baselga, A Manikhas, J Cortés, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 24, 1999
Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy
C Hudis, A Seidman, J Baselga, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 10, 2014
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer
J Baselga, A Manikhas, J Cortés, et al.
Breast Cancer Research and Treatment
|
May 19, 2015
Pegylated liposomal doxorubicin plus cyclophosphamide followed by paclitaxel as primary chemotherapy in elderly or cardiotoxicity-prone patients with high-risk breast cancer: results of the phase II CAPRICE study
Miguel J Gil-Gil, M Bellet, S Morales, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 28, 2018
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
S Loibl, I Majewski, V Guarneri, et al.
Page
of 17